UTRS vs. GNCA, AHPI, KLDO, VIVE, VRAYQ, NOVNQ, HGEN, STAB, NYXH, and STVN
Should you be buying Minerva Surgical stock or one of its competitors? The main competitors of Minerva Surgical include Genocea Biosciences (GNCA), Allied Healthcare Products (AHPI), Kaleido Biosciences (KLDO), Viveve Medical (VIVE), ViewRay (VRAYQ), NVN Liquidation (NOVNQ), Humanigen (HGEN), Statera Biopharma (STAB), Nyxoah (NYXH), and Stevanato Group (STVN). These companies are all part of the "medical" sector.
Minerva Surgical (NASDAQ:UTRS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, community ranking, valuation, earnings, risk and dividends.
In the previous week, Genocea Biosciences had 2 more articles in the media than Minerva Surgical. MarketBeat recorded 2 mentions for Genocea Biosciences and 0 mentions for Minerva Surgical. Minerva Surgical's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.
Minerva Surgical has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.
Genocea Biosciences has lower revenue, but higher earnings than Minerva Surgical. Minerva Surgical is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.
Genocea Biosciences received 381 more outperform votes than Minerva Surgical when rated by MarketBeat users. Likewise, 59.42% of users gave Genocea Biosciences an outperform vote while only 41.18% of users gave Minerva Surgical an outperform vote.
0.6% of Genocea Biosciences shares are held by institutional investors. 8.5% of Minerva Surgical shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Genocea Biosciences has a net margin of 0.00% compared to Minerva Surgical's net margin of -64.71%. Minerva Surgical's return on equity of -136.40% beat Genocea Biosciences' return on equity.
Summary
Genocea Biosciences beats Minerva Surgical on 8 of the 13 factors compared between the two stocks.
Get Minerva Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Minerva Surgical Competitors List
Related Companies and Tools
